Article by Gage Peake, Leafly
UK drugmaker GW Pharmaceuticals announced Tuesday it has achieved positive results in the second phase of a clinical study on Glioma, a cannabinoid-based therapy aimed at treating an aggressive form of brain cancer.
The study looked at 21 patients with recurrent glioblastoma multiform, or GBM, and found that participants who were given the drug—a combination of THC and CBD—lived significantly longer than those who took a placebo.
“These promising results are of particular interest as the pharmacology of the THC:CBD product appears to be distinct from existing oncology medications and may offer a unique and possibly synergistic option for future glioma treatment,” the study’s principal investigator Susan Short, an oncology professor at the Leeds Institute of Cancer and Pathology at St. James University Hospital, said in a statement.
Study participants who received Glioma showed an 83 percent one-year survival rate, GW reported, compared to a 52 percent rate among those who took a placebo. The median survival rate was 550 days among those who took the drug and 369 days among those who did not.
While the company says the treatment was “generally well tolerated” by patients, there were some observed side effects. Most common were vomiting, dizziness, nausea, headache, and constipation.